biostudies-literatureBai SNCI NIH HHS249-252https://www.ebi.ac.uk/biostudies/studies/S-EPMC6498725biostudies-literatureUnknown21(3)The development and progression of metastatic castration-resistant prostate cancer is the major challenge in the treatment of advanced prostate cancer. The androgen receptor signaling pathway remains active in metastatic castration-resistant prostate cancer. Docetaxel and cabazitaxel are the first- and second-line chemotherapy, respectively, for patients with metastatic castration-resistant prostate cancer. These two taxanes, in general, function by (i) inhibiting mitosis and inducing apoptosis and (ii) preventing microtubule-dependent cargo trafficking. In prostate cancer, taxanes have been reported to inhibit the nuclear translocation and activity of the androgen receptor. However, whether this is attainable or not clinically remains controversial. In this review, we will provide a comprAsian journal of andrologyImpact of taxanes on androgen receptor signaling.PMC6498725R01 CA188609Bai SDong YZhang BYfalseImpact of taxanes on androgen receptor signaling.The development and progression of metastatic castration-resistant prostate cancer is the major challenge in the treatment of advanced prostate cancer. The androgen receptor signaling pathway remains active in metastatic castration-resistant prostate cancer. Docetaxel and cabazitaxel are the first- and second-line chemotherapy, respectively, for patients with metastatic castration-resistant prostate cancer. These two taxanes, in general, function by (i) inhibiting mitosis and inducing apoptosis and (ii) preventing microtubule-dependent cargo trafficking. In prostate cancer, taxanes have been reported to inhibit the nuclear translocation and activity of the androgen receptor. However, whether this is attainable or not clinically remains controversial. In this review, we will provide a compr2019-01-01T00:00:00Z2019 May-Jun2025-05-29T22:12:37.251Z2025-05-29T22:12:37.251ZS-EPMC64987252990088210.4103/aja.aja_37_18